Elobixibat: a novel treatment for chronic constipation
Keywords:
Chronic constipation, Elobixibat ileal bile acid transporter, Inhibitor ileum bile acid transporterAbstract
Chronic idiopathic constipation (CIC) is a common functional bowel disorder. CIC affects about 14–20% of the world population, with a higher prevalence in females and elderly people. It has a significant impact on the quality of life and on the health care system. Particularly, in elderly patients with constipation, straining may increase blood pressure, and burden the heart, and blood vessels, which can lead to myocardial infarction, heart failure, and stroke. The diagnosis is based on symptoms, classified by the Rome IV criteria. Osmotic laxatives, particularly polyethylene glycol, are the first-line therapeutic approach. Stimulant laxatives are recommended as a second-line therapy. Unfortunately, these treatment options often exhibit limited efficacy. Approximately thirty to fifty percent of the patients with chronic constipation were not fully satisfied with the efficacy of these treatments, and there are gaps in satisfaction between physicians and patients regarding treatment. Therefore, this study reviewed the latest literature on the effect and safety of Elobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor for the treatment of chronic idiopathic constipation.
References
Salari N, Ghasemianrad M, Ammari-Allahyari M, Rasoulpoor S, Shohaimi S, Mohammadi M. Global prevalence of constipation in older adults: a systematic review and meta-analysis. Wien Klin Wochenschr. 2023;Feb 24.
Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(9):1582-91; quiz 1581, 1592.
Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep. 2017;19(4):15.
Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599-608.
Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(11):831-44.
Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66(4):948-83.
Marasco G, Cremon C, Barbaro MR, Falangone F, Montanari D, Capuani F, et al. Pathophysiology and Clinical Management of Bile Acid Diarrhea. J Clin Med. 2022;11(11):3102.
Ikeda N, Taniguchi S, Seki M. Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE((R)) tablet 5 mg). Nihon Yakurigaku Zasshi. 2019;153(3):129-38.
Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(10):1270-5.e1.
Camilleri M, Vijayvargiya P. The Role of Bile Acids in Chronic Diarrhea. Am J Gastroenterol. 2020;115(10):1596-603.
Camilleri M. Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol. 2014;8(1):49-61.
Vijayvargiya P, Busciglio I, Burton D, Donato L, Lueke A, Camilleri M. Bile Acid Deficiency in a Subgroup of Patients with Irritable Bowel Syndrome with Constipation Based on Biomarkers in Serum and Fecal Samples. Clin Gastroenterol Hepatol. 2018;16(4):522-7.
Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8(2):159-65.
Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139(5):1549-58, 1558.e1.
Misawa N, Higurashi T, Takatsu T, Iwaki M, Kobayashi T, Yoshihara T, et al. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. Aliment Pharmacol Ther. 2020;52(5):821-8.
Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology. 2013;144(1):145-54.
Taniguchi S, Yano T, Imaizumi M, Manabe N. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs. Neurogastroenterol Motil. 2018;30(12):e13448.
Chedid V, Vijayvargiya P, Camilleri M. Elobixibat for the treatment of constipation. Expert Rev Gastroenterol Hepatol. 2018;12(10):951-60.
Gillberg P, Dahlstrom M, Starke I, Ostlund-Lindqvist A. The IBAT inhibition by A3309 a potential mechanism for the treatment of constipation. Gastroenterol Clin North Am. 2010;138:S224.
Simren M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study. Aliment Pharmacol Ther. 2011;34(1):41-50.
Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011;106(10):1803-12.
Kumagai Y, Amano H, Sasaki Y, Nakagawa C, Maeda M, Oikawa I, et al. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial. Br J Clin Pharmacol. 2018;84(10):2393-404.
Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106(12):2154-64.
Nakajima A, Seki M, Taniguchi S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J Gastroenterol. 2018;53(4):525-34.
Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(8):537-47.
Rudling M, Camilleri M, Graffner H, Holst JJ, Rikner L. Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord. 2015;15:75.
Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297(5):499-508.
Salmoirago-Blotcher E, Crawford S, Jackson E, Ockene J, Ockene I. Constipation and risk of cardiovascular disease among postmenopausal women. Am J Med. 2011;124(8):714-23.
Charach G, Grosskopf I, Rabinovich A, Shochat M, Weintraub M, Rabinovich P. The association of bile acid excretion and atherosclerotic coronary artery disease. Therap Adv Gastroenterol. 2011;4(2):95-101.
Nakajima A, Taniguchi S, Kurosu S, Gillberg PG, Mattsson JP, Camilleri M. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan. Neurogastroenterol Motil. 2019;31(5):e13571.
Kang SJ, Cho YS, Lee TH, Kim SE, Ryu HS, Kim JW, et al. Medical Management of Constipation in Elderly Patients: Systematic Review. J Neurogastroenterol Motil. 2021;27(4):495-512.
Ishiyama Y, Hoshide S, Mizuno H, Kario K. Constipation-induced pressor effects as triggers for cardiovascular events. J Clin Hypertens (Greenwich). 2019;21(3):421-5.
Tomie A, Yoshida N, Kugai M, Hirose R, Dohi O, Inoue K, et al. The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study. Gastroenterol Res Pract. 2020;2020:9656040.
Abe T, Kunimoto M, Hachiro Y, Ohara K, Inagaki M, Murakami M. Efficacy and Safety of Elobixibat in Elderly Patients with Chronic Constipation: A Single-center, Observational Study. J Anus Rectum Colon. 2020;4(3):122-7.
Nakajima A, Fujimaki M, Arai Y, Emori K. Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance. J Neurogastroenterol Motil. 2022;28(3):431-41.
Kamei D, Kamei Y, Nagano M, Mineshima M, Nitta K, Tsuchiya K. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study. BMC Gastroenterol. 2020;20(1):26.
Shono T, Hyakutake H. Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study. Renal Replacement Therapy. 2020;6(1):21.
Matsuyama M, Hirai K, Nonaka H, Ueda M, Morino J, Kaneko S, et al. Effects of Elobixibat on Constipation and Lipid Metabolism in Patients With Moderate to End-Stage Chronic Kidney Disease. Front Med (Lausanne). 2021; 8:780127.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Chaiyaphum Medical Journal : ชัยภูมิเวชสาร
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
